Pyridoxine
FDA Approved
Description
Pyridoxine (Vitamin B6) is used in the treatment of hereditary sideroblastic anemia, particularly X-linked sideroblastic anemia caused by ALAS2 mutations. It acts as a cofactor for delta-aminolevulinic acid synthase, the first enzyme in heme biosynthesis. Some patients with hereditary sideroblastic anemia respond to high-dose pyridoxine supplementation with improved hemoglobin levels.
Indications & Therapeutic Use
Hereditary sideroblastic anemia, pyridoxine-responsive anemia, vitamin B6 deficiency
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pyridoxine
| Generic Name | Pyridoxine |
| Active Ingredient | Pyridoxine hydrochloride |
| Drug Class | Hereditary sideroblastic anemia |
| Manufacturer | Various |
| Dosage Forms | Oral tablets 25mg, 50mg, 100mg; Injectable solution 100mg/mL |
| Medical Code | A11HA02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes